Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Conditions
Keywords
Extensive-stage small cell lung cancer (ES-SCLC), Adebrelimab
Brief summary
The purpose of this observational study is to evaluate the safety and efficacy of Adebrelimab Injection in extensive-stage small cell lung cancer (ES-SCLC) under real-world conditions. Specifically, the study aims to assess the treatment of Adebrelimab Injection across various subgroups of ES-SCLC patients. The goal is to provide information on treatment patterns and effectiveness in real-life settings, explore potential predictive or prognostic biomarkers, and preliminarily evaluate the pharmacoeconomic indicators of Adebrelimab Injection treatment for extensive-stage small cell lung cancer.
Detailed description
This trial is a multicenter, non-interventional real-world study aimed at evaluating the safety and efficacy of Adebrelimab in the treatment of extensive-stage small cell lung cancer (ES-SCLC). The study plans to enroll 2000 patients with extensive-stage small cell lung cancer, collecting relevant information such as demographics, medical history, treatment regimens including Adebrelimab, clinical outcomes, and adverse events. Patients who have already decided to receive Adebrelimab treatment before enrollment will be categorized into one of the following two cohorts based on their disease stage and prior treatments: Cohort 1: First-line treatment for advanced stage Cohort 2: Second-line and beyond for advanced stage The Adebrelimab-containing treatment regimen for each patient will be assessed and selected by the investigator, and some treatment regimens are provided in this protocol for reference. After patients discontinue Adebrelimab treatment, they will be followed up until death, loss to follow-up, withdrawal of informed consent/voluntary withdrawal, or study termination/closure, whichever occurs first. As this is an observational study, treatments, procedures, visits, and examinations are based on the routine clinical experience of the attending physicians. The examinations listed in the protocol are recommended or for reference, with no mandatory requirements. The primary source of data for this study will be patients' routine medical records. During the period of Adebrelimab treatment, data on the administration regimen, routine examinations, adverse events, concomitant medications, and efficacy evaluations will be collected. When patients permanently discontinue Adebrelimab treatment for any reason (including but not limited to disease progression, intolerable toxicity, patient request, etc.), the reasons for discontinuation, adverse events/serious adverse events (up to 90 days after the last dose of Adebrelimab), the time of radiographic disease progression (if not the reason for discontinuation), subsequent anti-tumor treatments, and survival follow-up data will be collected. This study will explore potential predictive or prognostic biomarkers for ES-SCLC, so patients are requested to provide 10 tumor tissue slides whenever possible.
Interventions
DRUGFirst-line Adebrelimab regiment for advanced stage ES-SCLC
First-line Adebrelimab in any regiment for advanced stage ES-SCLC
DRUGSecond-line and beyond Adebrelimab regiment for advanced stage ES-SCLC
Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC
Sponsors
Shanghai Pulmonary Hospital, Shanghai, China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients must meet all of the following criteria to be eligible for inclusion in this study: 1. Voluntarily sign the informed consent form and agree to participate in the study. 2. Histopathologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC). 3. Age ≥ 18 years. 4. Determined by the investigator to be eligible for Adebrelimab treatment.
Exclusion criteria
* Patients with any of the following conditions are not eligible for inclusion in this study: 1. Evidence of being a pregnant or lactating female. 2. Currently receiving treatment as part of a blinded study protocol. 3. Any other condition that the investigator deems unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety (The occurrence of ≥3 grade AEs) | From August 2024, patients will be followed up for 90 days after the last use of Adebrelimab | The occurrence of ≥3 grade AEs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | Up to 2 years. From date of enrollment until the date of first documented progression, assessed up to 2 years. | Progression free survival from Adebrelimab treatment |
| OS | Up to 2 years. From date of enrollment until the date of death from any cause, assessed up to 2 years. | Overall survival from Adebrelimab treatment |
| DoR | Up to 2 years. From date of enrollment until the date of first documented progression, assessed up to 2 years. | Duration of response of Adebrelimab treatment |
| ORR | Up to 2 years. From date of enrollment until the date of first documented progression, assessed up to 2 years. | Objective response rate of Adebrelimab treatment |
| DCR | Up to 2 years. From date of enrollment until the date of first documented progression, assessed up to 2 years. | Disease control rate of Adebrelimab treatment |
Contacts
Primary ContactKeyi Jia, MD.PHD.
Backup ContactLibo Luo, MD.Master.
Outcome results
None listed